Elotuzumab Plus Pomalidomide or Lenalidomide is Able to Achieve Durable ?Vgpr Responses Among Immunomodulatory/Proteasome Inhibitor Refractory Myeloma Patients: A Report on Multicenter Experience From Turkey

Basit Öğe Kaydı
dc.authoridCengiz Seval, Guldane/0000-0001-9433-2054
dc.authoridPaydas, Semra/0000-0003-4642-3693
dc.authoridKaynar, Leylagul/0000-0002-2035-9462
dc.authoridBeksac, Meral/0000-0003-1797-8657
dc.authoridGURMAN, Gunhan/0000-0002-1263-8947
dc.authoridatalay, figen/0000-0003-4384-2913
dc.authoridAladag, Elifcan/0000-0002-1206-9908;
dc.authorwosidCengiz Seval, Guldane/GXV-6155-2022
dc.authorwosidAlbayrak, Murat/JUU-5382-2023
dc.authorwosidPaydas, Semra/F-3132-2018
dc.authorwosidKaynar, Leylagul/F-6991-2013
dc.authorwosidBeksac, Meral/D-6411-2013
dc.authorwosidKızıl Çakar, Merih/GYA-1392-2022
dc.authorwosidsonmez, mehmet/AAL-6243-2021
dc.contributor.authorBeksac, Meral
dc.contributor.authorSeval, Guldane Cengiz
dc.contributor.authorPaydas, Semra
dc.contributor.authorTuglular, Tulin Firatli
dc.contributor.authorArslan, Onder
dc.contributor.authorGoker, Hakan
dc.contributor.authorKaynar, Leylagul
dc.date.accessioned2024-06-12T11:00:13Z
dc.date.available2024-06-12T11:00:13Z
dc.date.issued2019
dc.departmentTrakya Üniversitesien_US
dc.description.abstract[Abstract Not Available]en_US
dc.identifier.doi10.1016/j.clml.2019.09.402
dc.identifier.endpageE243en_US
dc.identifier.issn2152-2650
dc.identifier.issn2152-2669
dc.identifier.issue10en_US
dc.identifier.startpageE242en_US
dc.identifier.urihttps://doi.org/10.1016/j.clml.2019.09.402
dc.identifier.urihttps://hdl.handle.net/20.500.14551/20752
dc.identifier.volume19en_US
dc.identifier.wosWOS:000491229800399en_US
dc.identifier.wosqualityQ3en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.language.isoenen_US
dc.publisherCig Media Group, Lpen_US
dc.relation.ispartofClinical Lymphoma Myeloma & Leukemiaen_US
dc.relation.publicationcategoryKonferans Öğesi - Uluslararası - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectElotuzumaben_US
dc.subjectImmunomodulatory Drugsen_US
dc.subjectMultiple Myelomaen_US
dc.titleElotuzumab Plus Pomalidomide or Lenalidomide is Able to Achieve Durable ?Vgpr Responses Among Immunomodulatory/Proteasome Inhibitor Refractory Myeloma Patients: A Report on Multicenter Experience From Turkeyen_US
dc.typeConference Objecten_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu